Released on = February 9, 2007, 6:37 am

Press Release Author = Anadis

Industry = Healthcare

Press Release Summary = Australian biopharmaceutical company Anadis Limited
(ASX:ANX) to establish a US subsidiary to focus on products against Influenza,
Nosocomial Infections such as MRSA, Clostridium dificilie, IBD, IBS and Biodefense
agents such as Anthrax and Plague.

Press Release Body = Australian biopharmaceutical company Anadis Limited (ASX:ANX)
announces the signing of an agreement to establish a US subsidiary. This fully owned
subsidiary will leverage on the Anadis R&D programs, expanding commercial and
research programs, establishing commercial partners and gaining access to public and
private funding within the important US market.
Anadis Ltd will utilise the services of BioVance Medical LLC to provide the
management for this new entity being established during the first half of 2007

BioVance Medical has experience and expertise in pharmaceutical development and
commercialisation and links into the US research and pharmaceutical community and
the Israeli clinical trial system.
BioVance Medical will also provide strategic advice in capital raising and funds
procurement through private and public equity sources, and research and development
granting agencies, particularly in the US. The principals of BioVance Medical LLC
have over 35 years of experience between them in the areas of Health Care, Capital
Markets and Product Commercialisation.

The R&D programs to be concentrated on for further expansion into this market include:
. Influenza A virus program - focussing on prevention and treatment
. Nosocomial infections program - in particular, Clostridium dificile and MRSA
(\"golden staph\")
. BioDefence program - respiratory protection against anthrax, plague and other
bio-warfare agents.
. Travelan antibodies for the treatment of inflammatory bowel disease and irritable
bowel syndrome (IBD and IBS)
On establishment of the US subsidiary, Anadis will appoint the two principles of
BioVance Medical LLC to operate the US subsidiary. Dr. Zeil Rosenberg is to be
appointed Managing Director and Dr. Oren Fuerst is to be appointed Chief Financial
Officer.

Zeil Rosenberg, MD, MPH
Dr. Rosenberg is a recognized physician-leader and business executive with 20 years
of achievement in the global healthcare industry. He served for 8 years at Becton
Dickinson & Co. as Worldwide Business Leader and Medical Director for Immunization
where he led a dedicated global team responsible for development, commercialization,
and marketing of a broad portfolio of specialized medical devices and systems for
safe delivery of vaccines. In the bio-defense arena, Dr. Rosenberg led initiatives

for delivery of bio-defense vaccines and solutions for mass immunization, such as
for influenza or smallpox, helping bring new products from concept through clinical
studies and into the marketplace.
Prior to joining industry, Dr. Rosenberg was National Director, The Children's
Health Fund in New York and Director, Family Health, New York State Department of
Health. In the international arena, Dr. Rosenberg served as a national health
advisor to the Ministry of Health of Indonesia and as AAAS Science and Diplomacy
Fellow at USAID in Washington, D.C. He has worked closely with efforts by UNICEF and
the American Red Cross in their global immunization initiatives to eliminate
neonatal tetanus and measles. Dr. Rosenberg serves as Chairperson, Committee on
Terrorism and Emergency Preparedness at the American College of Preventive Medicine
and is on the faculty of Columbia University's Mailman School of Public Health.
Dr. Rosenberg is a Specialty Fellow, American Academy of Pediatrics and Fellow,
American College of Preventive Medicine. He earned his MD at the University of
California, San Francisco and completed his residency at Cornell University Medical
Center. He received his MPH in Epidemiology from Columbia University and BA in
Economics from Stanford University.

Oren Fuerst, Ph.D.
Dr. Fuerst brings more than 15 years of experience in strategy and capital markets,
serving as a senior financial and strategy advisor to several prominent (including
Fortune 500) companies and investors in a variety of sectors.
He is the managing director of Strategic Models LLC, an advisory and investment
company based in NYC, and of its joint venture BioVance Medical LLC, which is
focused on advancing life sciences technologies.
Dr. Fuerst was on the faculty and served as the co-director of the Technology
Strategy and Valuation Executive Program at Columbia Business School, where he also
lectured on technology strategy and global valuation. He was a faculty member and
fellow at the International Center for Finance at the Yale University's School of
Management, lecturing and conducting research on International Investments and
Management Systems.
Prior to these, he was with the capital markets advisory group of KPMG Israel, and
was a feature columnist for leading financial newspapers (including the Financial
Times), advising and writing extensively on strategy, technology and investments. He
served as a commander in the elite Technology unit of the Israeli Defense Forces
(IDF).
Dr. Fuerst is the co-author of the books \"From Concept to Wall Street\" (Financial
Times-Prentice Hall, 2003) and "Startup Companies and Venture Capital" (Tel Aviv
University Press, 2001). He holds B.A. degrees in Economics and Accounting from
Tel-Aviv University (dual Magna Cum Laude), and both Masters and Ph.D. degrees from
Columbia Business School, where his theses were on the topics of game theory and
global equity markets.

About Anadis Limited:
Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and
Pharmaceutical research and development. Anadis is a specialist in the development
of Dairy (bovine) colostrum derived products for therapeutic use in humans.

Projects include:
-Anadis' first commercialised product: Travelan is a natural product, which
significantly decreases the risk of the medical condition known as Travellers
Diarrhoea (E. coli) and the symptoms of gastrointestinal disorders. For more
information please visit www.travelan.com
-EV-71 - a bioactive protein based preventative product against Enterovirus 71, a
debilitating polio like disease, is one of the viruses that causes 'hand, foot and
mouth' or 'slapped cheek' disease. A significant proportion of younger children
effected can develop nervous signs such as fits, paralysis and Enterovirus 71 has
the potentially to be fatal. Marketing of the product is expected on the northern
hemisphere summer of 2007.
-Bio-Defence Technologies focused on short-term immediate protection from airborne
bacteria such as Anthrax and Plague.
-Bio-Shielding technologies to protect delicate molecules, enzymes and proteins,
initially targeted for use in the pro-biotic market.
-Pyloran- clinically proven to reduce levels of H.pylori bacteria in the stomach and
reduce the symptoms of H.pylori associated gastritis - Anadis is also in early
development of a H.pylori vaccine.


Web Site = http://

Contact Details = Oren Fuerst, oren.fuerst@biovancemedical.com